| Azerbaijan | Turkey | Austria | |
| Therapeutic Apheresis | - | from $1,350 | - |
| Selective Apheresis | - | from $1,550 | - |
| Plasmapheresis | - | from $1,200 | from $2,000 |
| Plasma Exchange | - | from $3,900 | - |
| Lymphoma chemotherapy | - | from $3,000 | from $8,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Hematology Oncology treatment upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Hematology Oncology treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Hematology Oncology treatment journey.
Dr. Aydogdu specializes in early detection of pediatric cancers, focusing on improving outcomes for young patients at Liv Bona Dea Hospital Baku.
Written by Anna Leonova
Written by Anna Leonova
Written by Halina Shubala
Patients receiving hematology-oncology treatments in Azerbaijan may experience short-term side effects like hair loss and fatigue. Long-term risks include peripheral neuropathy and cognitive changes. Accredited centers like Liv Bona Dea Hospital Baku or the National Center of Oncology provide multidisciplinary support to manage these concerns.
Bookimed Expert Insight: Liv Bona Dea Hospital Baku serves 200,000 patients yearly and was ranked by Bookimed for excellence in blood disorders and cancer treatment in 2019. This high patient volume allows specialist doctors like Dr. Selime Aydogdu and Tural Pashayev to refine supportive care protocols for complex conditions like leukemia and myeloma. Patients should prioritize JCI-accredited facilities in Baku to ensure international safety standards for managing treatment toxicity.
Patient Consensus: Patients note that fatigue is often more intense than expected and not easily relieved by rest. They also emphasize that neuropathy and memory issues can persist long after treatment ends, making early discussions about these risks essential.